Consulting Report

Garau, M., Mordoh, A. and Sussex, J.

Consulting Report
April 2011

Continuing concern about the fiscal deficit makes it likely that government funding of health and medical research will remain under scrutiny. This OHE Consulting study, commissioned by Cancer Research UK, explores the interdependence between publicly funded and charity funded medical research.  In particular, it focuses on whether and how changes in the levels of government funding can affect private funding for charities, medical research and the UK economy as a whole.

Towse, A., Devlin, N., Hawe, E. and Garrison, L.

Consulting Report
January 2011

This report examines and makes suggestions for the appropriate use of health technology assessment (HTA) in emerging markets. In particulary, it considers how the stage of development of the health care system affects the relevance and appropriate use of various types of HTA. The approach developed then is used to analyse the options for Brazil, China and Taiwan.

Mestre-Ferrandiz, J., Garau, M., O'Neill, P. and Sussex, J.

Consulting Report
November 2010

This report examines the effect of the European Union’s 1999 Regulation on Orphan Medicinal Products (OMPs) on the European economy and society.  This study collected data on several indicators of activity, completed a confidential survey of companies developing OMP, concluded four case studies and undertook a literature review.  The result is a rich tableau of data and information that describe the effects of the OMP Regulation in some detail.  Findings include the following.

Sussex, J., Shah, K. and Butler, J.

Consulting Report
October 2010

This research reviews how vaccines other than for travel or influenza are evaluated, procured and delivered in Australia. It includes observations as to whether and how the economic assessment process differs for vaccines compared to curative pharmaceutical products and implications of central purchasing for economic efficiency.

Sussex, J. and Shah, K.

Consulting Report
October 2010

This research reviews how vaccines other than for travel or influenza are evaluated, procured and delivered in the UK. It includes observations as to whether and how the economic assessment process differs for vaccines compared to curative pharmaceutical products and the implications of the current pricing approach.

Mestre-Ferrandiz, J., Puig-Peiro, R. and Towse, A.

Consulting Report
October 2010

Ten member companies of the EFPIA HTA Task Force commissioned OHE consulting to provide research, data and analysis that would enable EFPIA both to support and develop its policy position and to contribute positively to the emerging dialogue around the development of HTA within Europe.

This research was designed to:

Mestre-Ferrandiz, J. and Sussex, J.

Consulting Report
September 2009

The debate continues as to whether public/charitable research replaces private research that otherwise would have occurred, or stimulates additional private research, or does neither. Given the extent of public and charitable biomedical research, the debate is particularly intense.

Garau, M., Shah, K., Towse, A., Wang, Q., Drummond, M.F. and Mason, A. R.

Consulting Report
February 2009

Lower usage of cancer medicines in the UK compared to other countries has created questions, including whether the current approach by NICE to assessing cancer medicines is an important factor in lower use in the UK. This Report is based on both a detailed literature review and interviews with key experts directly involved in the work of UK HTA bodies.

Health Economics Research Group, Office of Health Economics and RAND Europe.

Consulting Report
November 2008

Understanding the nature, extent and processes involved in the return on investment in medical research has been largely neglected as an area of serious scientific study. This report is the outcome of a one-year study commissioned by the UK Academy of Medical Sciences, the UK Medical Research Council and the Wellcome Trust. Its purpose is to compare the economic benefits accruing in the UK from medical research funded in the UK, publicly or by charities only, to the cost of that research.

Gray, A., Fenn, P., Garau, M., Pritchard, C., Godber, E. and Towse, A.

Consulting Report
December 2006

Objective To model the cost-effectiveness for donors of investing in R&D projects into global diseases via public private partnerships for product development (PD PPPs).

Pages

Subscribe to RSS - Consulting Report